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Abstract
Genome-scale high-throughput sequencing enables the detection of unprecedented
numbers of sequence variants. Variant filtering and interpretation are facilitated by
mutation databases, in silico tools, and population-based reference datasets such as
ExAC/gnomAD, while variants are classified using the ACMG/AMP guidelines. These
methods, however, pose clinically relevant challenges. We queried the gnomAD dataset
for (likely) pathogenic variants in genes causing autosomal-dominant disorders. Further-
more, focusing on the fibrillinopathies Marfan syndrome (MFS) and congenital
contractural arachnodactyly (CCA), we screened 500 genomes of our patients for co-
occurring variants in FBN1 and FBN2. In gnomAD, we detected 2653 (likely) pathogenic
variants in 253 genes associated with autosomal-dominant disorders, enabling the esti-
mation of variant-filtering thresholds and disease predisposition/prevalence rates. In
our database, we discovered two families with hitherto unreported co-occurrence of
FBN1/FBN2 variants causing phenotypes with mixed or modified MFS/CCA clinical fea-
tures. We show that (likely) pathogenic gnomAD variants may be more frequent than
expected and are challenging to classify according to the ACMG/AMP guidelines as
well as that fibrillinopathies are likely underdiagnosed and may co-occur. Consequently,
selection of appropriate frequency cutoffs, recognition of digenic variants, and variant
classification represent considerable challenges in variant interpretation. Neglecting
these challenges may lead to incomplete or missed diagnoses.
K E YWORD S
congenital contractural arachnodactyly, digenic variants, genome sequencing, Marfan
syndrome, variant interpretation
1 | INTRODUCTION
Current high-throughput sequencing (HTS) technologies such as
whole-exome (WES) and whole-genome sequencing (WGS) enable
the detection of ten thousands and millions of sequence variants,
respectively. For Mendelian disorders, the identification of typically
one or two disease-causing sequence variants represents a bottleneck
in the filtering and interpretation of the large number of sequence var-
iants detected by HTS. As sequence variants causing Mendelian disor-
ders are expected to be rare,1 filtering for sequence variants absent or
infrequent in population-based reference datasets is one of the mainArash Najafi and Sylvan M. Caspar contributed equally to this work.
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approaches used to discriminate (likely) pathogenic from benign vari-
ants. ExAC and its successor gnomAD are currently the largest pub-
licly available population-based reference datasets, providing the best
variant frequency estimates.2,3 Cutoffs of low allele frequencies are
often used, including 1%, 0.1%, or 0.01%.4,5 Recently, a gene-specific
framework has been introduced, which accounts for disease preva-
lence, allelic and genetic heterogeneity, inheritance mode, and pene-
trance, resulting in cutoff values even below 0.01%.6
Frequency cutoffs below 1%, however, may not be applicable to
all clinical cases. Indeed, in apparently healthy population-based refer-
ence datasets low-allele-frequency cutoffs may not appropriately
account for common genetic modifiers or for the considerable number
of disease-affected individuals with atypical, late-onset, and/or
unrecognized phenotypes. Moreover, recent reports of pseudo and
true digenic inheritance indicate that the identification of a single
disease-causing variant may be insufficient.7-9 Neglecting these fac-
tors may result in the exclusion of clinically relevant sequence vari-
ants, leading to incomplete or even missed diagnoses. Here, we
address these challenges by assessing the presence and frequency of
a priori (likely) pathogenic variants in gnomAD as well as by showing
hitherto unreported cases of digenic variants causing clinically rele-
vant complex phenotypes.
2 | MATERIALS AND METHODS
2.1 | Evaluation of gnomAD
We compared the gnomAD-based relative frequencies of most likely
pathogenic variants in the genes COL1A1, COL3A1, FBN1, FGFR2,
JAG1, KMT2D, NSD1, SCN1A, TSC1, and TSC2 with the previously
reported prevalence rates of respective autosomal-dominant disor-
ders. In addition, we compared the carrier frequencies of selected
known pathogenic variants causing pediatric and/or adult-onset disor-
ders in the genes BRCA1, BRCA2, CFTR, GJB2, and HBB among ExAC,
gnomAD, and currently appreciated estimates as described.10 We
hypothesized that such a comparison of observed and expected fre-
quencies enables to assess whether or not (likely) pathogenic variants
are overrepresented in gnomAD and, hence, gnomAD can be consid-
ered as representative for the general population (incl. individuals with
genetic predisposition to adult-onset autosomal-dominant disorders).
2.2 | Detection of pathogenic variants in gnomAD
Variant call format files containing all sequence variants in gnomAD
were downloaded from gnomAD.broadinstitute.com/downloads
(r2.0.1; 123 136 exomes and 15 496 genomes; released 2017, genome
build GRCh37/hg19) and parsed using LeftAlignAndTrimVariants con-
tained in GATK 3.5.11 Using VarSeq 2.0.1 (Golden Helix, Montana), the
downloaded gnomAD sequence variants were annotated with several
datasets and in silico tools (Supporting Information Table S1). To restrict
the analysis to high-confidence calls, we excluded sequence variants
with a non-PASS gnomAD filter, a 75-mer mappability <1,12 or a posi-
tion outside of the canonical transcript (Table “knownCanonical” in the
track “UCSC Genes” from the UCSC Table browser; genome.ucsc.edu/
cgi-bin/hgTables) as well as indels with a length ≥50 bp. To assess the
presence and frequency of (likely) pathogenic variants in gnomAD, we
performed automated filtering using VarSeq as well as manual evalua-
tion. Only genes exclusively associated with autosomal-dominant disor-
ders (status “confirmed” in OMIM version 2018.5, omim.org) and with a
DOMINO score ≥0.9 were selected.13 To restrict our analyses to genes
likely intolerant to loss-of-function (LOF) variants, only genes with a pLi
score ≥0.9 and an “observed/expected” (o/e) metric 90% confidence
interval upper bound <0.35 in gnomAD were further considered
(Figure 1).2 Genes associated with disorders inherited in an autosomal-
recessive or X-linked manner were not analyzed, because for the
gnomAD dataset (r2.0.1) information on haplotype and sex is not (yet)
available.
As prime examples, we focused on the genes FBN1 and FBN2,
which cause the autosomal-dominant fibrillinopathies Marfan syn-
drome (MFS, OMIM #154700) and congenital contractural
arachnodactyly (CCA, OMIM #121050), respectively.14,15 In addition
to nonsense, frameshift, and splicing variants, FBN1 and FBN2
sequence variants disrupting the consensus calcium-binding sequence
as well as disrupting or creating disulfide-bond-forming cysteines are
known to be damaging and MFS/CCA-causing due to increased pro-
teolytic degradation.16-19 Thus, such FBN1 and FBN2 sequence vari-
ants may be considered as a priori (likely) pathogenic, allowing the
more elaborate gnomAD-based predisposition/prevalence assessment
of fibrillinopathies.
We considered following sequence variants as most likely patho-
genic in six (I-VI) categories (Figure 1): (I) Nonsense and frameshift
variants with or without expected nonsense-mediated mRNA decay,
because both may cause disease but via separate mechanisms;20,21
(II) Single nucleotide variants located at the canonical splice sites
(exonic ±1 bp, intronic ±1-2 bp) and in silico predicted to alter splicing
(Supporting Information Table S1); (III) In-frame indels;22,23
(IV) Missense variants disrupting functionally critical amino acids in
the calcium-binding epidermal growth factor domains of FBN1 and
FBN2 such as disulfide-bond-forming cysteines as well as amino acids
Asn, Asp, and Glu directly binding calcium (uniprot.org/uniprot/
P35555; uniprot.org/uniprot/P35556);16-19 (V) Sequence variants not
included in categories I-IV but described as disease-causing (DM) in
the Human Gene Mutation Database (HGMD) professional (v2019.1;
portal.biobase-international.com) and/or as pathogenic in ClinVar
(v2019.5; ncbi.nlm.nih.gov/clinvar) in association with MFS or CCA
and with clear evidence for pathogenicity (segregation analysis, func-
tional assays); (VI) Missense variants in FBN1 and FBN2 not included
in categories I-V but classified as “damaging” or “deleterious” by all six
corresponding in silico prediction tools (FATHMM, FATHMM-MKL,
MutationAssessor, MutationTaster, Polyphen2, SIFT) without addi-
tional evidence (Supporting Information Table S1).
Subsequently, categories I-II were applied to the entire gnomAD
dataset, whereas categories III-VI were only applied to FBN1
(NM_000138.4, all exons) and FBN2 (NM_001999.3, CCA-mutation-
hotspot exons 23-34).24 Categories I-V were defined as sensu stricto
selected, that is, sequence variants with clear evidence for
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pathogenicity, while category VI contains sensu lato selected
sequence variants, that is, additional, potentially pathogenic variants
requiring manual expert review and interpretation. To largely exclude
false-positive results (ie, indeed non-pathogenic variants), we manu-
ally evaluated all gnomAD variants in categories I and II occurring
above a low-frequency cutoff value of 0.01% or affecting genes with
a total frequency of >1:2000.5 Accordingly, variants were excluded if
one of the following criteria was met: (a) ≥1 “benign” classifications in
HGMD and/or ClinVar; (b) >10% allele frequency in any gnomAD sub-
population; (c) variant exclusively affects weakly expressed exon
(<10% of the highest expressed exon in disease-relevant
tissue according to gtexportal.org).
2.3 | Detection of FBN1/FBN2 dual variants in
WGS data
WGS (PCR-free, 60× 150PE) of 500 individuals with rare, mainly car-
diovascular or connective tissue disorders was performed as
described.25 FASTQ files were aligned using GENALICE MAP
(Genalice, Nijkerk, The Netherlands).26 Variant calling was performed
using the Population Calling module of GENALICE MAP to simulta-
neously extract all FBN1 and FBN2 sequence variants in our data-
base.26 Using VarSeq, called sequence variants were annotated and
filtered for individuals harboring (likely) pathogenic variants in both
FBN1 and FBN2 (ie, dual variants). As a second interpretation plat-
form, the artificial-intelligence-driven interpretation software Moon
(Diploid, Leuven, Belgium) was used to independently detect FBN1/
FBN2 dual variants. For the confirmation of detected FBN1 and FBN2
variants and segregation analyses, Sanger sequencing of the
corresponding region was performed as described.27 Data on clinical
phenotypes were collected from medical records and/or during physi-
cal examination by one of the authors (A.N., M.R., or B.S.). Written
informed consent was obtained from patients and family members.
2.4 | ACMG/AMP classifications
Automated classifications using the American College of Medical
Genetics and Genomics (ACMG) and the Association for Molecular
Pathology (AMP) published guidelines were obtained from InterVar
v.201904/hg19.28 For FBN1 variants disrupting disulfide-bond-
forming cysteines, the ACMG/AMP criterion PM1 (moderate evi-
dence for pathogenicity) was manually adjusted to PS3 (strong
evidence for pathogenicity) as previously suggested.29 To avoid a bias
caused by the ACMG/AMP criterion PM2 (moderate evidence for
pathogenicity) fulfilled for variants absent from control populations,
the automated classification was manually adapted by applying the
criterion PM2 for extremely rare gnomAD variants as well (allele
count ≤2). Likewise, for the two families with FBN1/FBN2 dual
F IGURE 1 Overview of used workflow.
Categories I and II were applied to all genes
associated with autosomal-dominant
disorders in gnomAD, whereas categories III-
VI were only applied to FBN1 and FBN2. *,†
Data obtained from the
Tables “wgEncodeCrgMapabilityAlign75mer”
(*) and “knownCanonical” (†) from the UCSC
Table browser; genome.ucsc.edu/cgi-bin/
hgTables. ‡ Data obtained from the Online
Mendelian Inheritance in Man (OMIM)
dataset, 05.2018; omim.org. § According to
Quinodoz et al. (2017).13 ¶ According to Lek
et al. (2016).2 ** According to Karczewski
et al. (2019).3 †† In FBN2 the prevalence
calculation was limited to the CCA-mutation-
hotspot region (exons 23-34) for categories
II-VI, while for category I (nonsense and
frameshift) all exons were considered. ‡‡
Sequence variants predicted “damaging” or
“deleterious” by all six used in silico
prediction tools (FATHMM, FATHMM-MKL,
MutationAssessor, MutationTaster,
Polyphen2, SIFT; see also Supporting
Information Table S1). CCA, congenital
contractural arachnodactyly; gnomAD,
Genome Aggregation Consortium; HGMD,
Human Gene Mutation Database; indel,
insertion/deletion; MFS, Marfan syndrome
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variants, segregation data (PP1) were manually adjusted in the
classification.
2.5 | Statistical analysis
The upper and lower limits of the 95% confidence interval (CI) of a
proportion were calculated using the online tool VassarStats with a
correction for continuity (vassarstats.net/prop1.html) or the software
GraphPad Prism 8 (GraphPad Software, California). Proportion of
genetic predisposition and disease prevalence was calculated under
the assumption that carrier individuals in gnomAD harbor no more
than one (likely) pathogenic sequence variant in the considered
gene(s).
3 | RESULTS
3.1 | Detection of pathogenic variants in gnomAD
Our comparison revealed that the evaluated carrier frequencies in the
genes BRCA1, BRCA2, CFTR, GJB2, and HBB are not overrepresented
in gnomAD (Supporting Information Table S2), confirming ExAC-based
previous results.10 In categories I and II (Figure 1), considering all
gnomAD sequence variants in genes associated with autosomal-
dominant disorders (pLi ≥0.9, upper bound of the o/e metric 90% CI
<0.35) we identified by software filtering and manual evaluation a
total of 2653 a priori (likely) pathogenic variants in 253 genes. Ten of
these genes are the major cause of disorders with previously reported
prevalence but we found no clear evidence that gnomAD-based pred-
isposition/prevalence rates are significantly higher than reported esti-
mates (Supporting Information Figure S1). Per gene, 1 up to
130 gnomAD individuals harbor an a priori (likely) pathogenic variant
with relative allele frequencies ranging from 1/246 272 (0.0004%) to
82/183 872 (0.0446%; ATXN7 c.2673delA; Supporting Information
Figure S2), resulting in disease predisposition/prevalence estimates
ranging from approximately 1:100 000 to approximately 110:100 000
not associating with pLi, o/e, or DOMINO values (Supporting
Information Table S3, Supporting Information Figure S2). During man-
ual evaluation, we detected 16 apparently a priori (likely) pathogenic
variants, which we subsequently reclassified as (likely) non-pathogenic
and thus excluded from the analysis. This reclassification was due to
the less frequent allele being the reference allele in GRCH37/hg19 or
to miscalled deletion/insertion variants or because the sequence vari-
ants are exclusively present in a weakly expressed exon (Supporting
Information Table S4 and Table S5).
For the more elaborate predisposition/prevalence assessment of
fibrillinopathies, we considered sequence variants of categories I-V
(sensu stricto selected, Figure 1) in the genes FBN1 (all exons) and
FBN2 (CCA-mutation-hotspot exons 23-34), thereby identifying most
likely MFS- and CCA-causing variants in 67 and 39 gnomAD individ-
uals, respectively (Table 1, Figure 2, Supporting Information Table S6).
Furthermore, from category VI (sensu lato selected, Figure 1) we
added additional 880 FBN1 and 321 FBN2 missense variants that
were in silico predicted to be (likely) deleterious, leading to a total of
947 and 360 potentially MFS- and CCA-causing variants, respectively.
Accordingly, the gnomAD-based predisposition to MFS and CCA
ranges from 4.8:10 000 (95% CI: 4-6:10 000) up to 68:10 000
(95% CI: 64-72:10 000) and 2.8:10 000 (95% CI: 2-4:10 000) up to
26:10 000 (95% CI: 23-29:10 000), respectively, depending whether
sensu stricto and/or lato selected variants were considered (Table 1).
In gnomAD, the majority of the sensu stricto selected FBN1 and FBN2
sequence variants were detected in individuals aged ≥50 years and
were rare, with a non-reference allele count of 1. However, the three
most frequent sensu lato selected FBN1 variants, c.3890A>G
(289 of 299 non-reference alleles in Latino), c.3896C>T (70 of 73
TABLE 1 Overview of likely disease-causing FBN1 and FBN2 variants in gnomAD
FBN1 exons 23-34 FBN1 all exons FBN2 exons 23-34 FBN2 all exons
Nonsense and frameshift (category I) 2 8 5 29a (27)
Splicing (category II) 0 26 (10) 0 36 (25)
In-frame indels (category III) 1 9 (6) 0 8 (5)
Disulfide bonds (category IV) 1 8 4 36 (31)
Calcium binding (category IV) 4 12 (12) 6 (5) 49 (23)
HGMD 2019.1/ClinVar 2019.5 (category V)b 1 4 (3) 0 0
Sensu stricto selected sequence
variants (categories I-V) / (Prevalence)
9:138 632 /
(0.65:10 000)
67:138 632 /
(4.83:10 000)
39:138 632 /
(2.81:10 000)
158:138 632 /
(11.40:10 000)
Sensu lato selected sequence variants (category VI)c 566 (40) 880 (162) 321 (71) 1.999 (301)
All variants (categories I-VI) / (Prevalence) 575:138 632 /
(41.48:10 000)
947:138 632 /
(68.31:10 000)
360:138 632 /
(25.97:10 000)
2,157:138 632 /
(155.59:10 000)
All individuals in gnomAD (exomes and genomes) 138 632
Note: Numbers indicate the total number of variants, while numbers in parenthesis indicate the number of unique variants.
Abbreviations: gnomAD, Genome Aggregation Consortium; HGMD, Human Gene Mutation Database; indel, small insertion/deletion.
aNonsense/frameshift variants were counted regardless of their position in FBN2.
bOnly sequence variants not already included in categories I-IV and passing manual evaluation were counted.
cSequence variants predicted as "damaging" or "deleterious" by all of the six used in silico prediction tools (FATHMM, FATHMM-MKL, MutationAsessor,
MutationTaster, PolyPhen2, SIFT) not contained in I-V were counted; see also Supporting Information Table S1.
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non-reference alleles in Latino), and c.3089A>G (64 of 69 non-
reference alleles in South Asian) were predominant in one gnomAD
subpopulation, indicating a founder effect or selection bias (Supporting
Information Table S6).
3.2 | Evaluation of in silico prediction tools and
ACMG/AMP classifications
Splicing (category II) and functionally critical missense (category IV)
variants in FBN1 and FBN2 served as a set of positive controls for the
used in silico prediction tools (Supporting Information Table S1). All
but two missense variants disrupting disulfide-bond-forming cysteines
were correctly identified as “damaging” or “deleterious” by all six used
in silico missense prediction tools, whereas five sequence variants dis-
rupting calcium binding were missed by at least one tool. In contrast,
41, 38, and 21 of the 47 sensu stricto selected FBN1 variants were
classified as variant of unknown significance (VUS) according to the
ACMG/AMP guidelines by using automated classification, manually
adjusting variants disrupting disulfide-bond-forming cysteines from
PM1 to PS3,29 and applying the criterion PM2 for extremely rare
(allele count ≤2 in gnomAD) variants, respectively (Supporting
Information Table S6). All splicing (category II) and functionally critical
missense (category IV) variants were identified as phylogenetically
conserved by at least one of the three used conservation scores
(PhastCons, PhyloP, and SiPhy; Supporting Information Table S1), of
which the SiPhy score generated the fewest apparently false-negative
results (Supporting Information Table S6). The CADD algorithm, capa-
ble of predicting the effect of all types of sequence variants, assigned
high values to the majority of the sensu stricto selected sequence var-
iants, but it also scored six FBN1/FBN2 sequence variants in
categories I-V below a conservative PHRED-scaled CADD cutoff
score of 20 (Supporting Information Table S6).
3.3 | Evaluation of HGMD and ClinVar entries
Sixty-six and two entries not contained in categories I-IV were classi-
fied as DM (ie, disease-causing mutations; not to be confused with
the ACMG/AMP classification pathogenic and likely pathogenic) in
HGMD (v2019.1), while six and none were classified as pathogenic in
ClinVar (v2019.5) for MFS and CCA, respectively. By manual evalua-
tion of corresponding publications/entries, segregation or functional
analyses provided proof of pathogenicity for three of the FBN1
HGMD DM entries, which, but no FBN2 variant, could be included in
category V (Table 1).
3.4 | Families with pathogenic variants in both FBN1
and FBN2
In our cohort of 500 genomes, screening for individuals harboring
(likely) pathogenic variants in both FBN1 and FBN2 resulted in two
unrelated individuals (index patients with dual variants). Segregation
analysis by Sanger sequencing of family members revealed a further
dual variant carrier as well as individuals harboring only one or none of
the sequence variants (Table 2). Affected family members were physi-
cally examined, revealing overlapping as well as distinguishing MFS and
CCA clinical features (Table 2, Supporting Information Table S7).
The female index patient of Family 1 (Ab2) (Figure 3A), who was
referred with suspected CCA, harbors the heterozygous FBN2
branch-point variant c.3974-26T>G causing in-frame exon skipping
(p.Asn1327_Val1368del) first described as segregating with CCA in
F IGURE 2 FBN1 and FBN2 a priori (likely) pathogenic variants in gnomAD and FBN1/FBN2 dual variants in Family 1 and Family 2. Lollipops
show the type and position of variants in relation to protein domain structure. Red boxes indicate the severe/neonatal region in FBN1 (exons
23-34) and the comparable congenital contractural arachnodactyly (CCA)-mutation-hotspot region in FBN2 (exons 23-34). cbEGF, calcium-
binding epidermal growth factor; EGF, epidermal growth factor; HGMD, Human Gene Mutation Database; indel, small insertion/deletion; TB,
transforming growth factor β binding. Information on protein domains was obtained from umd.be/FBN1 and umd.be/FBN2. Lollipop diagrams
were generated using the R package “trackViewer,” available from bioconductor.org/packages/release/bioc/html/trackViewer.html
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TABLE 2 Clinical features observed in Family 1 and Family 2 harboring sequence variants in FBN1 and FBN2
Family 1 Family 2
Clinical features Ab6 Ab1 Ab2 Ab4 Ab3 Ac3 Ac1 Ac2
Age at examination (years) /
Sex
70 / M 15 / F 12 / F 45 / M 46 / F 58 / F 21 / M 53 / M
Affected gene FBN1 FBN1 FBN1/FBN2 FBN1/FBN2 FBN2 FBN1 FBN1/FBN2 FBN2
MFS-associated features55
Pes valgus + − − + − − − (+)
Pes planus (+) + + + + + + −
Pneumothorax − − − − − − − +a
Reduced elbow extension
(r / l)
+ / + >180 / >180 + / + + / + – / – >180 / >180 >180 / >180 – / –
3 of 5 facial features
(dolichocephaly,
enophthalmus, malar
hypoplasia, retrognathia,
downslanting fissures)
− − − − − − + −
Skin striae + − − − (+) − − +
Myopia (>3 diopters) − + − − − − + +
Aortic dilatation (cm) n/a − − + (4.9)
(Z.score: >2.0)
− − + (4.1)
(Z-score: >2.0)
−
Ghent nosology systemic
score
<7 <5 7 >7 <7 <5 >7 <7
CCA-associated features24
Contractures
Fingers (r / l) – / – – / – + / + + / + + / + – / – – / – + / +
Elbow (r / l) + / +b – / – + / + + / + – / – – / - - / - – / -
Hip n/a − − n/a n/a − − −
Knee (r / l) – / – – / - - / - – / - - / - – / - - / - – / -
Crumpled ears (remark) − − – (small ears) + − − − −
MFS- and CCA-associated
features
Palatal arch n/a narrow high n/a n/a normal high high
Mitral valve prolapse − − − − (+) − − −
US/LS ratio < 0.85 (height,
cm)
– (172) – (163.5) – (159) + (179.5) + (171) – (168) – (188) – (195)
Armspan/height ratio > 1.05
(armspan, cm)
– (180.5) – (163.5) – (159) – (188.5) – (179.5) – (169) + (205) – (198.5)
Scoliosis or thoracolumbar
kyphosis
(+) − + − (+) (+) + −
Wrist sign − − + + − − + +
Thumb sign − − + + − − + +
Pectus abnormity − + (carinatum) + (excavatum) + (carinatum &
excavatum)
(+) (carinatum) − + (carinatum) −
Note: Sequence variants detected in Family 1: FBN1 (NM_000138.4) c.8489A>G p.(Gln2830Arg) and FBN2 (NM_001999.3) c.3974-26T>G p.
(Asn1327_Val1368del), sequence variants detected in Family 2: FBN1 c.6595G>A p.(Gly2199Ser) and FBN2 c.3481G>A p.(Glu1161Lys).
Abbreviations: +, present; −, absent; (+), mildly present; CCA, congenital contractural arachnodactyly; F, female; l, left; LS, lower segment; M, male; MFS,
Marfan syndrome; n/a, information not available; r, right; US, upper segment.
aPneumothorax due to tuberculosis infection during adolescence.
bLikely explained by his old age of 70 years at examination.
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the large family of Ab2.30 In addition, she harbors the heterozygous
FBN1 variant c.8489A>G, p.(Gln2830Arg), not detected in gnomAD
and in silico predicted as (likely) deleterious. According to the
ACMG/AMP guidelines, these FBN2 and FBN1 variants can be classi-
fied as likely pathogenic (LP) and VUS, respectively (Supporting
Information Table S8). Ab2 presented with CCA-associated clinical
features such as elbow and finger contractures, but no MFS-
associated cardiovascular involvement (likely due to her young age of
12 years at examination). In addition, she presented with MFS/CCA-
overlapping features such as wrist and thumb sign (arachnodactyly),
pectus excavatum, and scoliosis (Table 2, Supporting Information -
Figure S3). The father of Ab2 (Ab4; first described as IV-9)30 harbors
the same FBN1/FBN2 variants and presented with similar clinical fea-
tures, but also with CCA-associated crumpled ears and MFS-
associated aortic dilatation (4.9 cm diameter, Z-score > 2.0). Ab1, the
sister of Ab2, only harbors the FBN1 variant and, as expected, pres-
ented with MFS-associated features such as elbow hyperextension,
myopia, and pectus carinatum. Ab6, the grandfather of Ab2, only har-
bors the FBN1 variant as well but presented with mild MFS/CCA-
overlapping scoliosis and CCA-associated elbow contractures at age
of 70 years at examination. Ab3, the aunt of Ab2, only harbors the
FBN2 variant and presented with CCA-associated finger contractures
and mild MFS/CCA-overlapping mitral valve prolapse and pectus
carinatum. Ab7, the grandmother of Ab2, also only harboring the
FBN2 variant was not available for clinical examination. Ab5, the
mother of Ab2, likely harbors neither sequence variant but was not
available for genetic testing and examination.
The male index patient in Family 2 (Ac1) (Figure 3B), who was
referred to us with suspected MFS, harbors the described (DM? in
HGMD)31 heterozygous FBN1 variant c.6595G>A, p.(Gly2199Ser),
which is in silico predicted as deleterious but detected three times in
gnomAD and thus classified as VUS according to the ACMG/AMP
guidelines. In addition, he harbors the reported (DM in HGMD)32 het-
erozygous FBN2 variant c.3481G>A, p.(Glu1161Lys), which is absent
from gnomAD, affects a calcium binding residue, and is predicted as
deleterious and classified as LP by in silico algorithms and the
ACMG/AMP guidelines, respectively (Table 2, Supporting
Information Table S8). Ac1 presented with MFS-associated features
such as elbow hyperextension, high myopia (−23/−23 dpt), and mild
aortic dilatation (4.1 cm; Z-score > 2.0) as well as MFS/CCA-
overlapping features such as severe lumbar scoliosis (surgically
corrected), wrist and thumb sign (arachnodactyly), high-arched palate,
and marfanoid habitus. However, he showed no CCA-associated con-
tractures (Table 2). Ac2, the father of Ac1, only harbors the FBN2 vari-
ant and presented with CCA-associated features such as finger
contractures, MFS/CCA-overlapping features like arachnodactyly and
high-arched palate, as well as high myopia (−12/−9 dpt), which is fre-
quent in MFS and may also occur in CCA.33,34 Both Ac3, the mother
of Ac1, and Ac4, the aunt of Ac1, only harbor the FBN1 variant and
presented with mild MFS phenotypes and non-marfanoid habitus. The
mother (Ac3) presented with MFS-associated elbow hyperextension,
mild scoliosis, and no cardiovascular involvement (Table 2), while the
aunt (Ac4) reportedly is of short stature with no cardiovascular
involvement, but was not available for clinical examination.
4 | DISCUSSION
Our data show that, with appropriate consideration, gnomAD, the
largest publicly available dataset for population-based allele frequen-
cies, can be used not only for variant filtering, interpretation, and car-
rier screening but also for the estimation of disease
predisposition/prevalence. Accordingly, we calculated gnomAD-based
predisposition/prevalence estimates for autosomal-dominant
F IGURE 3 Pedigrees of Family 1 (A) and Family 2 (B). Arrows denote index patients harboring FBN1/FBN2 dual variants. The vertical line in
the symbols (circle, female; square, male) denotes molecular genetic testing for the respective variants. Black halves (left) represent an FBN1
variant, striped halves (right) represent an FBN2 variant, and white halves represent absence of variant. The diagonal line through a symbol
indicates deceased family members. The age at examination (y, years) or the year of birth and, where applicable, death is given in parentheses
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disorders at genome scale, thereby providing a novel estimate for
MFS and the first estimate for CCA. Using the example of these
fibrillinopathies, we also showed that the genetic predisposition to
highly-penetrant autosomal-dominant disorders may occur more fre-
quently than previously assumed. Moreover, by presenting two fami-
lies with hitherto unreported co-occurrence of FBN1/FBN2 variants
causing increased or hidden clinical features of MFS and CCA, we
exemplified that segregating (ie, not-linked) pathogenic variants in
more than one gene can underlie the clinical phenotype of patients
and the clinical variability of affected family members. Thus, several
challenges and conclusions emerge.
First, although WGS is the most comprehensive HTS method
offering advantages over targeted sequencing and WES,25,35 data
interpretation remains a challenge.12 Currently, there is no generally
accepted gold standard software solution for variant interpretation
comparable to BWA/GATK for alignment and variant calling.11,12
According to the ACMG/AMP guidelines, allele frequencies higher
than expected for the disorder (criterion BS1) or reported >5% in
population-based reference datasets (criterion BA1) count as strong
or stand-alone evidence of benign impact of a variant.1 Accordingly,
low-frequency cutoffs are often used, down to <0.01%.6 Although
such cutoffs help to reduce or minimize the number of candidate vari-
ants, they may remove clinically relevant variants from consideration.
Examples include the sensu stricto selected FBN1 variant c.863A>G,
p.(Asp288Gly) (allele frequency: 12/277 018; 0.0043%) and the sensu
lato selected FBN1 variant c.3026C>G, p.(Pro1009Arg) (allele fre-
quency: 16/246 218; 0.0065%) (Supporting Information Table S6),
which are more frequent in gnomAD than the recently introduced
maximum tolerated allele count of 2 in approximately 120 000 alleles
(approximately 4/240 000; approximately 0.0017%) for MFS.6 In addi-
tion, low-frequency cutoffs exclude weaker variants such as the
homozygous Ehlers-Danlos syndrome causing but heterozygous
phenotype-modifying COL5A1 variant c.1588C>T, p.(Gly530Ser)36
and clinically relevant but common genetic modifiers like
chr1:203138970A>G (rs2250509)37 modifying the expressivity of
MYH7-related cardiomyopathy with gnomAD allele frequency of 3.4%
and 18.8%, respectively. Moreover, due to a founder effect or selec-
tion bias, certain potentially pathogenic variants requiring manual
expert review, including the three most frequently occurring FBN1
variants in category VI (c.3089A>G, c.3890A>G, and c.3896C>T in
Supporting Information Table S6), may occur rather frequently in one
ethnicity (up to 0.12% allele frequency) and thus may be filtered out
by using too low cutoff frequencies (ie, below 0.12%). Thus, filtering
for sequence variants extremely rare or absent in population-based
reference datasets is helpful to identify variants that should not be
missed in a first step, while variants with an increased frequency
should not be a priori disregarded without an appropriate consider-
ation and literature review, especially in complex cases.38 Additional
rare exonic variants may pose challenges for interpretation, such as
variants solely affecting weakly expressed exons or variants miscalled
as two independent variants instead of a small insertion/deletion
(Supporting Information Table S5). To avoid missed or incomplete
diagnoses, there is an evident demand for more advanced filtering
methods that may consider more elaborated algorithms, adapted cut-
offs, paralogue annotations,39 facial phenotyping algorithms,40 or data
sharing platforms.41
Second, although current widely-used in silico tools and disease-
associated databases are powerful, they are not without fault. In this
study, not all in silico tools correctly classified all of the sensu stricto
selected FBN1 and FBN2 variants. By individual use, these tools are
therefore not capable of depicting all of the underlying disease-
causing mechanisms and, hence, we recommend combining multiple
tools for the highest accuracy and the robust application of the
ACMG/AMP criteria PP3 and BP4.38 Moreover, several sequence var-
iants classified as DM in HGMD or pathogenic in ClinVar were consid-
ered for category V but were excluded, because manual evaluation of
the corresponding publication/entry revealed no convincing evidence
of pathogenicity (ie, functional characterization or segregation ana-
lyses). Thus, even in curated datasets such as HGMD and ClinVar
unreliable variant-disease associations might be present, which is why
they need to be used with care and evaluated by experts.42,43
Third, the ACMG/AMP guidelines provide a framework for clinical
variant classification.1 To support implementation and increase inter-
laboratory concordance,44 (semi-)automated open source (eg, Inter-
Var, Genetic Variant Interpretation Tool)28,45 and commercial (eg,
VarSome.org; Goldenhelix.com) classification tools have been devel-
oped. Furthermore, a refinement of the ACMG/AMP guidelines into
108 criteria46 as well as several gene- and disease-specific adaptations
have been introduced.29,47,48 However, because 10 of the
28 ACMG/AMP criteria need manual adjustment (eg, by using func-
tional or segregation data), the result obtained by (semi-)automated
classification is often incomplete, regardless of the applied tool.28
Unfortunately, information for manual adjustment is unavailable in
gnomAD and thus the ACMG classifications in this study are based on
automated classification, explaining why the majority of our positive
control variants in FBN1 were classified as VUS. This, however, would
likely be resolved using additional information. For instance, the
FBN1-specific refinement of the ACMG/AMP criteria led to a more
appropriate classification of disulfide-bond-disrupting FBN1 variants
as LP instead of VUS (Supporting Information Table S6).29 In addition,
not only because gnomAD contains pathogenic variants but also
because larger population datasets will emerge in the future, the crite-
rion PM2 (moderate evidence for pathogenicity; fulfilled for variants
absent from control populations) may require adjustment. As the
application of population-based data is a major source of inter-
laboratory discordances,38 increased number of population-based
criteria (eg, 5 criteria instead of the existing 3, PM2, BA1, BS1),46 or
gene-specific frequency thresholds6,48 could help to appropriately
implement the PM2 criterion. Indeed, in the absence of additional
information, application of the PM2 criterion to extremely rare vari-
ants (allele count ≤2 in gnomAD) may lead to a reclassification, for
example, from VUS (PVS1, PP3) to pathogenic (PVS1, PM2, PP3), rep-
resenting a major caveat. Moreover, the ACMG/AMP guidelines were
developed for highly-penetrant monogenic disorders, complicating
their implementation in cases with (pseudo) digenic inheritance or
with genetic modifiers (eg, because of the application of segregation
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data). As the ACMG/AMP guidelines are widely used, it is crucial to
use classification tools prudently and to understand their limitations.
Depending on the used tool, the thresholds for several criteria may
vary, leading to inconsistent or VUS classifications, which may be piv-
otal as the ACMG/AMP guidelines are frequently invoked for clinical
decision support47 and because VUS are not recommended to be
reported to patients.49
Fourth, as we detected 2653 a priori (likely) pathogenic gnomAD
variants in genes associated with autosomal-dominant disorders, this
dataset should be regarded as apparently, rather than completely, non-
affected. Nevertheless, our data suggest that (likely) pathogenic
variants are not overrepresented and we found no clear evidence for
considerable bias due to included disease-specific studies. Thus,
gnomAD can be considered as an appropriate representation of the
general population, thereby expanding the knowledge of pathogenic
variants in ExAC to the much larger gnomAD database,10 enabling (re-)
estimation of the population prevalence of genomic disorders. In gen-
eral, gnomAD genes of categories I-II (Figure 1) with an increased num-
ber of (likely) pathogenic variants are not infrequently associated with
highly-penetrant diseases with late onset and/or unapparent pheno-
type, which may occur in fibrillinopathies as well. Indeed, without
appropriate imaging of the aorta, even old (≥50 years) carriers of patho-
genic FBN1 and/or FBN2 variant(s) may be considered as apparently
non-affected in gnomAD. Our gnomAD-based MFS predisposition rate
of approximately 5:10 000 (FBN1 categories I-V) is higher than the pre-
viously reported prevalence of approximately 1-3:10 000,33,50
suggesting that highly-penetrant fibrillinopathies may be under-
diagnosed, especially in mild cases. However, FBN1 mutations have
been reported in other non-MFS disorders as well (cf. HGMD profes-
sional; portal.biobase-international.com). As for FBN2 we only consid-
ered the CCA-mutation-hotspot exons 23-34, the real predisposition to
CCA might be even higher than our estimate of approximately
3:10 000. In contrast, some of the detected a priori (likely) pathogenic
variants in gnomAD, although de facto (likely) pathogenic, might not
lead to disease in certain resilient individuals.51 Resilience may be due
to protective genetic modifiers or absence of expression of the affected
allele due to random monoallelic expression.52,53 Because we only con-
sidered PASS gnomAD variants (ie, genotype quality ≥20, allelic balance
>0.2, and read depth ≥10)2 with a mappability =1,12 the variants
included in this study are most likely true variants and do not result
from mosaicism or alignment difficulties.
Fifth, the presented two families with hitherto unreported FBN1/
FBN2 dual variants showing mixed phenotypes of MFS and CCA
exemplify the importance of considering clinically relevant pathogenic
variants in more than one gene. The presented cases neither fulfill the
definition of true digenic inheritance nor of classic genetic modifiers,
because the sequence variants alone also cause at least a mild pheno-
type and the dual variant carriers do not show novel but rather a com-
bination of MFS- and CCA-associated features.9,37 Thus, the
presented cases are most accurately described as two diseases segre-
gating independently according to classic Mendelian inheritance that
underlie the phenotype of dual variant carriers.9 According to our
data, the probability of the co-occurrence of FBN1 and FBN2 variants
in one individual might be at least approximately 1.36 × 10−7, imply-
ing that additional, unrecognized cases may exist.
As expected, only individuals harboring an FBN1 variant (with or
without the FBN2 variant) show MFS-associated aortic dilatation,
whereas only individuals harboring an FBN2 variant (with or without
the FBN1 variant) show CCA-associated contractures (Table 2). Individ-
uals carrying only the familial FBN1 variant (Ab1, Ab6, and Ac3) show
several features of MFS including joint laxity, indicating the clinically
relevant effect of both FBN1 variants classified as VUS according to the
ACMG/AMP guidelines (Table 2). The effect of dual variants appears
synergistic for some clinical features, which has also been observed in
an Fbn1/Fbn2 double knock-out mouse model.54 For instance, severe
kyphoscoliosis is exclusively present in the dual-variant carrier (Ac1) in
Family 2 (FBN1 c.6595G>A, FBN2 c.3481G>A) but in neither of the
parents (Ac2, Ac3). In addition, myopia is more pronounced in the dual-
variant carrier Ac1 (−23/−23 dpt) than in the FBN2 variant carrier Ac2
(−12/−8 dpt), suggesting a synergistic effect of both variants regarding
the ocular phenotype as well. In contrast, for other distinguishing clini-
cal features, the effect of one variant appears to be more pronounced,
because the dual-variant carriers (Ab2, Ab4) in Family 1 show CCA-
specific contractures, while the dual-variant carrier (Ac1) in Family
2 shows MFS-associated elbow hyperextension. If pathogenic variants
in more than one gene underlie the disease phenotype such as in the
presented cases, molecular genetic diagnosis is crucial for etiology-
oriented treatment and particularly for genetic counseling regarding
family planning. Thus, information on possible digenic inheritance
is clinically highly relevant and known cases are listed in the Digenic
Diseases Database (dida.ibsquare.be).
The main limitation of our study is that for gnomAD phenotypic
data of the participants is (yet) unavailable and thus the clinically rele-
vant effect of detected variants can not be directly assessed. Further-
more, information whether multiple sequence variants are harbored
by one individual is also unavailable in gnomAD, which would be nec-
essary to assess digenic inheritance and genetic modifiers. Moreover,
as we restricted our genome-scale analysis to categories I and II con-
taining a priori (likely) pathogenic variants (nonsense, frameshift, and
canonical splice sites), we potentially missed other (likely) pathogenic
variants. We considered that for some genes (eg, GFAP, TGFBR1,
TGFBR2) LOF is not (yet) established as a disease mechanism. Thus, to
exclude such genes, we restricted our analyses to genes likely intoler-
ant to LOF as predicted by both the pLi score and the o/e metric.2,3
Indeed, for all but one (ATXN7) of seven genes with (likely) pathogenic
gnomAD-based allele frequencies >1:2000 (Supporting Information -
Table S4), our manual evaluation revealed LOF as an established dis-
ease mechanism. On the other hand, although our data suggest that
variants causing severe (pediatric) diseases are likely not overrepre-
sented in gnomAD, the dataset includes disease-associated projects,
potentially biasing our gnomAD-based disease prevalence calcula-
tions. Thus, considering incomplete penetrance, variable expressivity
and late disease onset as well, the genome-scale prevalence values
presented here should be regarded as predisposition estimates, aiming
to highlight challenges in allele-frequency-based variant filtering and
HTS data interpretation.
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Taken together, in the current genomics era using appropriate short-
and/or long-read HTS platforms, the bottleneck on the path to accurate
diagnosis is the interpretation of variants rather than the generation of
data.12 Current interpretation approaches are challenged by VUS, inap-
propriate variant filtering, and unrecognized digenic inheritance/variants
or genetic modifiers, warranting improvement. Hence, instead of hard fil-
tering, variant interpretation should include large-scale deeply geno- and
phenotyped databases, powerful in silico tools, and data sharing as well
as, if available, appropriate segregation and functional analyses to aid
expert evaluation and enable accurate diagnosis.
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